Skip to content 
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts. more
| Time Frame | CRL | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -5.94% | -2.48% | -1.18% |
| 1-Month Return | 1.77% | -1.98% | -2.14% |
| 3-Month Return | -13.13% | -0.28% | -1.73% |
| 6-Month Return | 5.74% | 9.61% | 3% |
| 1-Year Return | 1.37% | 4.85% | 21.8% |
| 3-Year Return | -16.39% | 22.22% | 75.87% |
| 5-Year Return | -40.73% | 33.93% | 72.09% |
| 10-Year Return | 125.42% | 123.28% | 234.83% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 3.54B | 3.98B | 4.13B | 4.05B | 4.02B | [{"date":"2021-12-31","value":85.73,"profit":true},{"date":"2022-12-31","value":96.29,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":98.08,"profit":true},{"date":"2025-12-31","value":97.24,"profit":true}] |
| Cost of Revenue | 2.21B | 2.51B | 2.63B | 2.72B | 2.79B | [{"date":"2021-12-31","value":79.06,"profit":true},{"date":"2022-12-31","value":90.09,"profit":true},{"date":"2023-12-31","value":94.16,"profit":true},{"date":"2024-12-31","value":97.43,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | 1.33B | 1.46B | 1.50B | 1.33B | 1.23B | [{"date":"2021-12-31","value":88.82,"profit":true},{"date":"2022-12-31","value":97.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":88.64,"profit":true},{"date":"2025-12-31","value":81.57,"profit":true}] |
| Gross Margin | 37.70% | 36.79% | 36.39% | 32.88% | 30.52% | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.58,"profit":true},{"date":"2023-12-31","value":96.52,"profit":true},{"date":"2024-12-31","value":87.23,"profit":true},{"date":"2025-12-31","value":80.96,"profit":true}] |
| Operating Expenses | 744.78M | 811.68M | 885.29M | 1.10B | 717.73M | [{"date":"2021-12-31","value":67.43,"profit":true},{"date":"2022-12-31","value":73.49,"profit":true},{"date":"2023-12-31","value":80.16,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":64.98,"profit":true}] |
| Operating Income | 589.86M | 650.98M | 617.26M | 227.35M | 507.84M | [{"date":"2021-12-31","value":90.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.82,"profit":true},{"date":"2024-12-31","value":34.92,"profit":true},{"date":"2025-12-31","value":78.01,"profit":true}] |
| Total Non-Operating Income/Expense | (182.41M) | (86.50M) | (169.97M) | (251.95M) | (709.43M) | [{"date":"2021-12-31","value":-18241000000,"profit":false},{"date":"2022-12-31","value":-8649900000,"profit":false},{"date":"2023-12-31","value":-16997400000,"profit":false},{"date":"2024-12-31","value":-25194600000,"profit":false},{"date":"2025-12-31","value":-70943100000,"profit":false}] |
| Pre-Tax Income | 480.71M | 622.99M | 581.28M | 93.11M | (99.50M) | [{"date":"2021-12-31","value":77.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.31,"profit":true},{"date":"2024-12-31","value":14.95,"profit":true},{"date":"2025-12-31","value":-15.97,"profit":false}] |
| Income Taxes | 81.87M | 130.38M | 100.91M | 67.82M | 42.66M | [{"date":"2021-12-31","value":62.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":77.4,"profit":true},{"date":"2024-12-31","value":52.02,"profit":true},{"date":"2025-12-31","value":32.72,"profit":true}] |
| Income After Taxes | 398.84M | 492.61M | 480.37M | 25.29M | (142.16M) | [{"date":"2021-12-31","value":80.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.52,"profit":true},{"date":"2024-12-31","value":5.13,"profit":true},{"date":"2025-12-31","value":-28.86,"profit":false}] |
| Income From Continuous Operations | 398.84M | 492.61M | 480.52M | 25.29M | (142.16M) | [{"date":"2021-12-31","value":80.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.55,"profit":true},{"date":"2024-12-31","value":5.13,"profit":true},{"date":"2025-12-31","value":-28.86,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 390.98M | 486.23M | 474.62M | 10.30M | (144.34M) | [{"date":"2021-12-31","value":80.41,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.61,"profit":true},{"date":"2024-12-31","value":2.12,"profit":true},{"date":"2025-12-31","value":-29.69,"profit":false}] |
| EPS (Diluted) | 10.33 | 11.13 | 10.65 | 10.32 | 10.28 | [{"date":"2021-12-31","value":92.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.69,"profit":true},{"date":"2024-12-31","value":92.72,"profit":true},{"date":"2025-12-31","value":92.36,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| CRL | |
|---|---|
| Cash Ratio | 0.19 |
| Current Ratio | 1.29 |
| Quick Ratio | 1.02 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| CRL | |
|---|---|
| ROA (LTM) | 4.24% |
| ROE (LTM) | -4.23% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| CRL | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.55 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.44 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| CRL | |
|---|---|
| Trailing PE | NM |
| Forward PE | 16.29 |
| P/S (TTM) | 2.05 |
| P/B | 2.75 |
| Price/FCF | 141 |
| EV/R | 2.76 |
| EV/Ebitda | 26.94 |
| PEG | 0.13 |
Charles River Laboratories (CRL) share price today is $168.91
Yes, Indians can buy shares of Charles River Laboratories (CRL) on Vested. To buy
Yes, you can purchase fractional shares of Charles River Laboratories (CRL) via the Vested app. You can start investing in Charles River Laboratories (CRL) with a minimum investment of $1.
You can invest in shares of Charles River Laboratories (CRL) via Vested in three simple steps:
The 52-week high price of Charles River Laboratories (CRL) is $228.88. The 52-week low price of Charles River Laboratories (CRL) is $91.86.
The price-to-earnings (P/E) ratio of Charles River Laboratories (CRL) is
The price-to-book (P/B) ratio of Charles River Laboratories (CRL) is 2.75
The dividend yield of Charles River Laboratories (CRL) is 0.00%
The market capitalization of Charles River Laboratories (CRL) is $8.24B
The stock symbol (or ticker) of Charles River Laboratories is CRL
Consider the share price of Charles River Laboratories as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Charles River Laboratories has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Charles River Laboratories shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Charles River Laboratories stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Charles River Laboratories and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Charles River Laboratories stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
